Researchers are using food DNA in North Carolina wastewater to map community diets, with a closer neighborhood-level pilot now underway in Durham.

Northwestern has landed $20 million to build the nation’s first publicly accessible AI-powered protein engineering cloud lab. The Evanston facility could let researchers run sophisticated experiments remotely.

Dallas-based Sendero has acquired Plano AI and analytics firm Torq in an eight-figure deal that adds about 90 consultants and lifts combined revenue into the nine-figure range.

ASU will lead a DOE‑backed project to build AI that models thousands of grid scenarios so operators can spot risks and prioritize fixes across Arizona and beyond.

A UCLA study finds elementary students who own cellphones scored lower on reading comprehension, even when phones weren’t in the classroom.

Marlborough‑based Boston Scientific approved a global restructuring this week with $700–$800M in charges and plans to shift production — and some jobs — as it refocuses resources. The company says much of the savings will be reinvested in growth areas.

Galveston County is warning residents after 14 cyclosporiasis cases were confirmed. The parasite can bring a long, miserable stomach illness.

Nine institutional firms including BlackRock and Coinbase pledged $15M to fund post‑quantum research, tooling and audits as experts warn the timeline to a quantum threat is compressing.

Nvidia’s reported talks to underwrite OpenAI’s Ohio lease would fold a chip supplier into financing for the world’s largest AI campus, reviving circular‑financing concerns.

A UF research team is designing a forecasting app that uses years of removal records and weather cues to predict when and where Burmese pythons are most likely to be found in South Florida.

A UT Health San Antonio–led analysis finds frontotemporal dementia shows up differently in Hispanic patients — with more movement symptoms and longer diagnostic delays. The authors call for larger, culturally informed studies.

argenx agreed to buy Dallas‑based Forte for about $2.2 billion, folding Forte’s experimental anti‑CD122 drug FB102 into argenx’s immunology lineup.

A UC San Diego analysis of a randomized trial found semaglutide slowed DNA-based markers of aging in adults with HIV. Researchers say larger trials are needed to confirm clinical benefit.